Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Niessner

Showing results (181-190 of 207) with videos related to

Pageof 21
Sort By:
European Heart Journal|November 11, 2017
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyAlexander Niessner, Juan Tamargo, Lorenz Koller, et al.
European Heart Journal|September 10, 2013
High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortalityGuenther Silbernagel, Ben Schöttker, Sebastian Appelbaum, et al.
European Heart Journal|January 13, 2017
Comprehensive efforts to increase adherence to statin therapyAlexander Vonbank, Stefan Agewall, Keld Per Kjeldsen, et al.
Wiener Klinische Wochenschrift|April 2, 2026
[Consensus statement of the Austrian Society for Rheumatology and Rehabilitation on the management of increased cardiovascular risk in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis]Boris Lindner, Mathias Ausserwinkler, Christina Siess, et al.
Circulation. Heart Failure|August 15, 2015
Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection FractionLorenz Koller, Marcus E Kleber, Vincent M Brandenburg, et al.
European Heart Journal|December 26, 2015
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on ThrombosisAlexander Niessner, Juan Tamargo, João Morais, et al.
Plos One|April 8, 2015
Association of small dense LDL serum levels and circulating monocyte subsets in stable coronary artery diseaseKonstantin A Krychtiuk, Stefan P Kastl, Stefan Pfaffenberger, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 29, 2022
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyJuan Tamargo, Keld Per Kjeldsen, Eva Delpón, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 2, 2020
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trialsHeinz Drexel, Basil S Lewis, Giuseppe M C Rosano, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 24, 2019
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on StrokePatrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
Pageof 21

Showing results (181-190 of 207) with videos related to

Sort By:
Pageof 21
European Heart Journal|November 11, 2017
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyAlexander Niessner, Juan Tamargo, Lorenz Koller, et al.
European Heart Journal|September 10, 2013
High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortalityGuenther Silbernagel, Ben Schöttker, Sebastian Appelbaum, et al.
European Heart Journal|January 13, 2017
Comprehensive efforts to increase adherence to statin therapyAlexander Vonbank, Stefan Agewall, Keld Per Kjeldsen, et al.
Wiener Klinische Wochenschrift|April 2, 2026
[Consensus statement of the Austrian Society for Rheumatology and Rehabilitation on the management of increased cardiovascular risk in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis]Boris Lindner, Mathias Ausserwinkler, Christina Siess, et al.
Circulation. Heart Failure|August 15, 2015
Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection FractionLorenz Koller, Marcus E Kleber, Vincent M Brandenburg, et al.
European Heart Journal|December 26, 2015
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on ThrombosisAlexander Niessner, Juan Tamargo, João Morais, et al.
Plos One|April 8, 2015
Association of small dense LDL serum levels and circulating monocyte subsets in stable coronary artery diseaseKonstantin A Krychtiuk, Stefan P Kastl, Stefan Pfaffenberger, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 29, 2022
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyJuan Tamargo, Keld Per Kjeldsen, Eva Delpón, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 2, 2020
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trialsHeinz Drexel, Basil S Lewis, Giuseppe M C Rosano, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 24, 2019
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on StrokePatrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
Pageof 21